Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;108(6):819-29.
doi: 10.1016/j.rmed.2014.03.008. Epub 2014 Apr 4.

Idiopathic pulmonary fibrosis: early detection and referral

Affiliations
Review

Idiopathic pulmonary fibrosis: early detection and referral

Justin M Oldham et al. Respir Med. 2014 Jun.

Abstract

Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3-5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Vigilance among clinicians in recognizing IPF early in the disease course remains critical to properly caring for these patients, as this provides the widest range of management options. When IPF is suspected, a multidisciplinary evaluation (MDE) by a clinician, radiologist and pathologist with ILD expertise should occur, as this improves diagnostic agreement in both community and academic settings. When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center should be considered. ILD center referral may also provide access specialized care, including clinical trials and lung transplantation, and should be considered for any patient with an established diagnosis of IPF.

Keywords: ILD; IPF; Lung transplant; Pulmonary fibrosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

Dr. Noth has received honoraria for advisory boards with Boehringer Ingelheim, InterMune, Anthera within the last 12 months related to IPF. He has also received speaking honoraria from GSK and receives consulting fees for Immuneworks. He also has study contracts with the NIH, Stromedix, Sanofi, and Boehringer Ingelheim for the conduct of clinical trials in IPF. Boehringer Ingelheim Pharmaceuticals, Inc. paid the processing charge for this article and was allowed to review the manuscript for factual accuracy with no editorial input.

Figures

Figure 1
Figure 1
Chest radiograph of a patient with IPF. Findings include asymmetric peripheral and basilar reticular opacity and lower lobe volume loss.
Figure 2
Figure 2
HRCT of the chest demonstrating classic UIP pattern. Findings include peripheral and basilar predominant reticulation with traction bronchiectasis and honeycombing.
Figure 3
Figure 3
Histopathologic UIP pattern. Low-power photomicrographs showing findings characteristic of UIP, including subpleural interstitial fibrosis (thin arrow) with temporal heterogeneity (normal lung at the lower right of each slide) and fibroblastic foci (thick arrow). (Courtesy of Aliya Husain, M.D., Department of Pathology, The University of Chicago).
Figure 4
Figure 4
Survival from the time of evaluation at a tertiary care center adjusted for age and FVC across quartiles of delay. Entry time into the cohort began at study enrollment. Reprinted from Ref. [72] with permission of the American Thoracic Society. Copyright © 2014 American Thoracic Society.

Similar articles

Cited by

References

    1. King TE., Jr Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005;172:268–279. - PubMed
    1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. - PubMed
    1. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199–203. - PubMed
    1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. - PMC - PubMed
    1. De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J. 2001;17:954–961. - PubMed

Publication types

MeSH terms

LinkOut - more resources